Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

Author： Bono Petri   Rautiola Juhana   Utriainen Tapio   Joensuu Heikki  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.4, 2011-05, pp. : 569-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite

Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient

By Medioni Jacques   Cojocarasu Oana   Banu Eugeniu   Cassar-Queudeville Alexia   Halimi Philippe   Oudard Stéphane  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 193-195

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis

By Ibrahim Ezzeldin   Kazkaz Ghieth   Abouelkhair Khaled   Bayer Ali   Elmasri Osama  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1060-1069

Springer Publishing Company

Access to resources Recommend Favorite

Axitinib in the treatment of metastatic renal cell carcinoma

By Ho Thai H   Jonasch Eric  

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1247-1253

Future Medicine

Access to resources Recommend Favorite

Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma

By  

Current Cancer Therapy Reviews, Vol. 1, Iss. 2, 2005-06 ,pp. : 127-137

Bentham Science Publishers

Access to resources Recommend Favorite